When was ImmunoGenesis founded?

ImmunoGenesis was founded in 2019 and raised its 1st funding round 5 years after it was founded.

Where is ImmunoGenesis located?

ImmunoGenesis is headquartered in Houston, United States. It is registered at 2450 HOLCOMBE BLVD STE J,HOUSTON,TX,77021,101.

Who is the current CEO of ImmunoGenesis?

James Barlow of ImmunoGenesis. They are also an angel investors in 1 startup.

How many employees does ImmunoGenesis have?

As of Aug 31, 2026, the latest employee count at ImmunoGenesis is 15.

Is ImmunoGenesis a funded company?

ImmunoGenesis is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Mar 18, 2024.

When was the latest funding round of ImmunoGenesis?

ImmunoGenesis' latest funding was a $***** Series C round on Mar 18, 2024, with participation from 0 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.98B in funding in 2026 to date.

Where does ImmunoGenesis rank among its competitors?

ImmunoGenesis ranks 257th amongst 3443 active competitors, of which 1154 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of ImmunoGenesis?

ImmunoGenesis' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

ImmunoGenesis - 2026 Company Profile, Team, Funding & Competitors

ImmunoGenesis is a series C company based in Houston (United States), founded in 2019 by Michael Curran. It operates as a Developer of immunotherapies targeting resistance mechanisms in solid tumor cancers. ImmunoGenesis has raised $44.4M in funding. The company has 3443 active competitors, including 1154 funded and 807 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of immunotherapies targeting resistance mechanisms in solid tumor cancers. These treatments aim to overcome immune exclusion by dismantling barriers that prevent immune cells from accessing and destroying tumor tissue. The therapeutic approach involves blocking inhibitory signals and modifying the tumor microenvironment to facilitate immune cell infiltration. The pipeline includes multifunctional antibodies and prodrugs designed to restore anti-tumor immunity in patients with solid tumors.

Website: www.immunogenesis.com/
Email ID: *****@immunogenesis.com
Phone Number: +1 **********
Registered Address: 2450 HOLCOMBE BLVD STE J,HOUSTON,TX,77021,101

Key Metrics

Founded Year

2019

Location

Houston, United States

Stage

Series C

Total Funding

$44.4M in 1 round

Latest Funding Round

Series C, Mar 18, 2024, $*****

Investors

Reimagined Ventures & 5 more

Ranked

257^th among 3443 active competitors

Employee Count

15 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3161 more

View ImmunoGenesis' full profile

ImmunoGenesis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Immunogenesis, Inc. CIN: 32071130275 , United States, Active	Jun 21, 2019	-	-	-

ImmunoGenesis has raised a total funding of $44.4M over 1 round. ImmunoGenesis has 6 institutional investors.

Here is the list of recent funding rounds of ImmunoGenesis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 18, 2024	9092470	Series C	8712693	8672138	4212639	3965727

Access funding benchmarks and valuations. Sign up today!

View details of ImmunoGenesis's funding rounds and investors

The founders of ImmunoGenesis is Michael Curran. James Barlow is the CEO of ImmunoGenesis.

Here are the details of ImmunoGenesis' key team members:

Michael Curran: Founder of ImmunoGenesis.
Contact Info: 1 email address
James Barlow: CEO of ImmunoGenesis. They are also an angel investor in 1 startup.
Contact Info: 1 email address

View details of ImmunoGenesis's Founder profiles and Board Members

ImmunoGenesis' employee count trend

ImmunoGenesis has 15 employees as of Aug 26. Here is ImmunoGenesis's employee count trend over the years:

Uncover ImmunoGenesis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ImmunoGenesis include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of ImmunoGenesis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
257th	ImmunoGenesis 2019, Houston (United States), Series C	Developer of immunotherapies targeting resistance mechanisms in solid tumor cancers	$44.4M	Reimagined Ventures, Adit Ventures & 4 others	58/100